

GLAXOSMITHKLINE PLC
Form 6-K
March 17, 2009

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the period ending 17th March 2009

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road,

Brentford,

Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark if the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-Fx Form 40-Fo

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yeso Nox

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Date: March 17th 2009

GlaxoSmithKline plc
(Registrant)

By: /s/ Victoria Whyte

VICTORIA WHYTE
Authorised Signatory for and on behalf of
GlaxoSmithKline plc

A new approach for 2008

This year we've taken a new approach to how we report to our shareholders. In place of the Annual Review we have published this short summary and have moved to more dynamic reporting on our website, where you can also find our full Annual Report.

Our aim is to keep you updated on our top level results via this summary, while also giving you the opportunity to access more detailed information through the Internet.

We are now also able to give you the option to receive email notifications of our annual results, please see the Shareholder Information section overleaf for details.

Our strategy for the future

Earlier this year we launched our new strategic priorities:

Grow a diversified global business

Deliver more products of value

Simplify the operating model

Underpinning the strategic priorities, which are outlined in this summary, are a number of detailed plans. You can keep up to date with our progress throughout the year by visiting the new **Our mission and strategy** section of our website www.gsk.com/mission-strategy

Everyone at GSK has a part to play in putting these plans into action, to contribute to our challenging and inspiring mission - enabling people to do more, feel better and live longer.

To find out more about GSK visit

www.gsk.com

Andrew Witty

Chief Executive Officer

Results and strategic priorities 2008

Our strategy

Grow

a diversified global business

Deliver

more products of value

Simplify

the operating model

In 2008 we set out three new strategic priorities that aim to improve our long-term financial performance.

We believe these priorities will enable us to navigate the coming years successfully and retain our leading-edge as a company able to meet patients and payers needs into the future.

Results and strategic priorities 2008

**Grow a diversified
global business**

We are reducing risk by broadening and balancing our portfolio, diversifying into new product areas that show potential, while also fully capturing opportunities for our products across all geographic boundaries.

The plans which underpin this strategic priority:

Drive growth in the pharmaceutical business in our core markets

Deliver our ambitious vaccines forecast

Fulfil the potential of emerging markets

Expand our business in Japan

Grow the Consumer Healthcare business

www.gsk.com/mission-strategy

Results and strategic priorities 2008

**Deliver more
products of value**

We are striving to build one of the strongest pipelines in the industry. We are transforming R&D to ensure that we not only deliver the current pipeline but are also able to sustain the flow of products for years to come.

The plans which underpin this strategic priority:

Focus on the best science

Diversify through externalisation

Re-personalise R&D

Focus on return on investment

www.gsk.com/mission-strategy

Results and strategic priorities 2008

**Simplify the
operating model**

GSK is a complex organisation. We recognise that we need to simplify our operating model further, changing the way we work, removing unnecessary processes and structures which slow us down and distract us from our mission.

The plans which underpin this strategic priority:

Evolve our commercial model

Re-shape manufacturing

Streamline our processes

Reduce working capital

www.gsk.com/mission-strategy

Results and strategic priorities 2008

A year in numbers

£24bn
Turnover

£4.7bn
Free cash flow

88.6p
Total earnings
per share

12
Products launched
in 2008

57p
Dividend
per share

30
Products in late stage
development

Results and strategic priorities 2008

At a glance

2008 performance summary

Total Group turnover was £24.4 billion, down 3% CER*, up 7% in sterling terms

Pharmaceutical turnover was £20.4 billion, down 3% CER, Consumer Healthcare turnover up 3% CER to £4 billion

Emerging Markets sales up 12% CER to £2.3 billion

Vaccines sales up 15% CER to £2.5 billion

EPS before major restructuring 104.7p down 9% CER, up 6% in sterling terms

Grow a diversified global business

Excluding genericised products, *Avandia* and pre-pandemic preparations, our core pharmaceuticals business had turnover of £16.4 billion and grew by 10%

Continued market share growth in Oral healthcare and Nutritional healthcare but sales fell in OTC due to lower sales of smoking cessation products

Transactions with Aspen and BMS executed to build broader and more geographically diverse portfolio

Deliver more products of value

12 key products launched, including *Tyverb*, *Volibris* and *Avamys* in Europe and *Treximet*, *Entereg*, *Promacta*, *Kinrix* and *Rotarix* in the USA.

Secured 17% of FDA approvals for new chemical entities and vaccines

Five new assets moved into phase III development during 2008

Created 35 Discovery Performance Units, small teams each with three-year funding in place

Entered or expanded 21 new drug discovery alliances

Simplify the operating model

Restructuring programme expanded to deliver annual savings of £1.7 billion by 2011

Rescaled and redeployed US pharmaceuticals sales force

Delivered more than £500 million of cash flow benefits from the working capital reduction programme which started in September 2008

* CER: Growth at constant exchange rates (CER) calculated as if exchange rates in 2008 had remained unchanged from those used in 2007.

Results and strategic priorities 2008

Summarised financial information

| | Results before major restructuring £m | Major restructuring £m | 2008 Total £m | Results before major restructuring £m | Major restructuring £m | 2007 Total £m |
|---|---|------------------------------|--|---|------------------------------|---------------------------------------|
| Summary income statement | | | | | | |
| Turnover | 24,352 | | 24,352 | 22,716 | | 22,716 |
| Operating profit | 8,259 | (1,118) | 7,141 | 7,931 | (338) | 7,593 |
| Profit before tax | 7,782 | (1,123) | 6,659 | 7,790 | (338) | 7,452 |
| Profit after tax | 5,551 | (839) | 4,712 | 5,571 | (261) | 5,310 |
| Profit attributable to minority interests | 110 | | 110 | 96 | | 96 |
| Profit attributable to shareholders | 5,441 | (839) | 4,602 | 5,475 | (261) | 5,214 |
| Earnings per share | | | 88.6p | | | 94.4p |
| Diluted earnings per share | | | 88.1p | | | 93.7p |
| Dividends per share | | | 57p | | | 53p |
| Summary balance sheet | | | | | | |
| | | | 2008 £m | | | 2007 £m |
| Non-current assets | | | 22,124 | | | 17,377 |
| Current assets | | | 17,269 | | | 13,626 |
| Total assets | | | 39,393 | | | 31,003 |
| Current liabilities | | | (10,017) | | | (10,345) |
| Non-current liabilities | | | (21,058) | | | (10,748) |
| Total liabilities | | | (31,075) | | | (21,093) |
| Net assets | | | 8,318 | | | 9,910 |
| Shareholders' equity | | | 7,931 | | | 9,603 |
| Minority shareholders' equity | | | 387 | | | 307 |
| Total equity | | | 8,318 | | | 9,910 |

| Summary cash flow statement | 2008 £m | 2007 £m |
|---|--------------------------|------------|
| Net cash inflow from operating activities | 7,205 | 6,161 |
| Net cash outflow from investing activities | (1,149) | (3,048) |
| Net cash outflow from financing activities | (4,908) | (1,702) |
| Increase in cash and bank overdrafts in the year | 1,148 | 1,411 |
| Exchange adjustments | 1,103 | 48 |
| Cash and bank overdrafts at beginning of the year | 3,221 | 1,762 |
| Cash and bank overdrafts at end of the year | 5,472 | 3,221 |

This document does not constitute a set of summary financial statements as defined under section 251 of the Companies Act 1985.

Our full 2008 Annual Report is available at
www.gsk.com/annualreport

Results and strategic priorities 2008

Shareholder information

More information on www.gsk.com

The information in this document is only a summary of certain information contained in our Annual Report for the year ended 31 December 2008 and does not contain all the information needed to give as full an understanding of the results, state of affairs, risks and uncertainties of the company and the Group as is provided by the full financial statements, Directors' Report, Remuneration Report and Auditors' Report contained in the Annual Report.

The Annual Report and the Notice of Annual General Meeting are available at

www.gsk.com/annualreport

Annual General Meeting

The GSK Annual General Meeting will be held at 2.30pm on Wednesday 20 May 2009 at:

The Queen Elizabeth II Conference Centre

Broad Sanctuary

Westminster

London SW1P 3EE

Keeping up to date

You may choose to receive future notifications from us by email by registering accordingly on www.shareview.co.uk.

You can request printed copies of our financial reports from:

Equiniti, the company's registrar in the UK; and from

The Bank of New York Mellon, the company's depository in the USA.

Shareholder and Investor contacts

| Security type | Contact address | Telephone |
|---|--|---|
| Ordinary shares, administered by Equiniti Limited | Aspect House Spencer Road Lancing BN99 6DA | 0871 384 2991 (inside the UK) +44(0) 121 415 7067 (outside the UK) |
| ADRs, administered by The Bank of New York Mellon | BNY Mellon Shareowner Services PO Box 358516 Pittsburgh, PA 15252-8516 | 1 877 353 1154 (US toll free) +1 201 680 6825 (outside the USA) |

Dividends

The Board has declared dividends for 2008:

| Dividend | Payment date | 2008 pence | 2007 pence |
|----------------|----------------|---------------|---------------|
| First interim | 10 July 2008 | 13 | 12 |
| Second interim | 9 October 2008 | 13 | 12 |

| | | | |
|----------------|----------------|-----------|----|
| Third interim | 8 January 2009 | 14 | 13 |
| Fourth interim | 9 April 2009 | 17 | 16 |
| Total | | 57 | 53 |

2009 dividend calendar

| Quarter | Ex-dividend date | Record date | Payment date |
|----------------|-------------------------|--------------------|---------------------|
| Q4 2008 | 11 Feb 2009 | 13 Feb 2009 | 9 Apr 2009 |
| Q1 2009 | 29 Apr 2009 | 1 May 2009 | 9 Jul 2009 |
| Q2 2009 | 29 Jul 2009 | 31 Jul 2009 | 8 Oct 2009 |
| Q3 2009 | 4 Nov 2009 | 6 Nov 2009 | 7 Jan 2010 |

Trademarks

Brand names appearing in italics throughout this publication are trademarks either owned by and/or licensed to GlaxoSmithKline group of companies, with the exception of *Entereg*, a trademark of Adolor Corporation in the USA, and *Volibris*, a trademark owned by Gilead, which are used in certain countries under licence by the Group.

Cautionary statement

Under the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions shareholders that any forward looking statements or projections made by the company, including those made in this Annual Summary, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under "Risk factors" in the "Business Review" in the company's Annual Report 2008.

Financial advice

The provision of the details on this page is not intended to be an invitation or inducement to engage in an investment activity. Advice on share dealing should be obtained from a stockbroker or independent financial adviser.

Results and strategic priorities 2008
